info@healthcostinstitute.org

mediA@healthcostinstitute.org

  • X
  • LinkedIn
  • Link
Search
Health Care Cost Institute
  • Home
  • Data
    • ESI Data Access Hub
    • Data Tools
    • Healthy Marketplace Index
    • Price Transparency Tool
  • Research
    • Original Reports
    • Health Care Cost & Utilization Report 
    • Health Care Vitals
    • Latest HCCI Reports
  • About HCCI
    • About Us
    • HCCI Staff
    • CEO & President
    • Careers
    • Governing Board 
Search

HCCI Reports

  • Use of and Spending on Top Prescription Drugs in Employer Sponsored Insurance, 2021

    Tags: Drug Spending, ESI
    Use of and Spending on Top Prescription Drugs in Employer Sponsored Insurance, 2021
    HCCI Staff
    May 25, 2023

    Recent policy and other initiatives aim to reduce spending on prescription drugs. At the federal level, the Inflation Reduction Act targets reductions in drug spending in Medicare through price negotiation, capping out-of-pocket spending by patients, and requiring drug manufacturers to pay rebates when prices rise faster than inflation. At the state level, there are initiatives…

    Read more: Use of and Spending on Top Prescription Drugs in Employer Sponsored Insurance, 2021
    • Facebook
    • X
    • LinkedIn
    • Pinterest
  • Over 80% of ESI Enrollees Used Evaluation and Management Services in 2021, with Primary Care and Telehealth the Most Commonly Used

    Tags: ESI, Utilization
    Over 80% of ESI Enrollees Used Evaluation and Management Services in 2021, with Primary Care and Telehealth the Most Commonly Used
    Linsay Sarfo, Zehra Valencia, Aditi Sen
    May 23, 2023

    Evaluation and Management (E&M) services provide an entry point for many people into the health care system. This category of services includes most office visits to a primary care physician or specialist, including behavioral health services, as well evaluation and management services provided in an emergency room or outpatient setting. These visits typically involve a…

    Read more: Over 80% of ESI Enrollees Used Evaluation and Management Services in 2021, with Primary Care and Telehealth the Most Commonly Used
    • Facebook
    • X
    • LinkedIn
    • Pinterest
  • The Price of Childbirth Can be Twice as High Even in the Same Hospital

    Tags: ESI, Maternal Health
    The Price of Childbirth Can be Twice as High Even in the Same Hospital
    Aditi Sen, Debbie Bozzi, Katie Martin
    May 12, 2023

    According to HCCI’s data, the price of a hospital admission for childbirth among birthing people with employer-sponsored health insurance (ESI) varies by a factor of three across hospitals within a local area. Even within the same hospital and within the same type of delivery, some births cost twice as much as others. Different prices for…

    Read more: The Price of Childbirth Can be Twice as High Even in the Same Hospital
    • Facebook
    • X
    • LinkedIn
    • Pinterest
  • From Prenatal through Postpartum Care, it Cost More Than $24,000 to Have a Baby on Average

    Tags: ESI, Maternal Health
    From Prenatal through Postpartum Care, it Cost More Than ,000 to Have a Baby on Average
    Zehra Valencia, Aditi Sen, Jessica Chang
    May 12, 2023

    Total Spending Averaged $24,336 across the Prenatal, Childbirth, and Postpartum Periods among ESI Enrollees HCCI has highlighted the high cost of childbirth in the United States, but delivery is only one component of the full financial cost of having a baby. The cost of prenatal and postpartum care may cause people to forgo appropriate services,…

    Read more: From Prenatal through Postpartum Care, it Cost More Than $24,000 to Have a Baby on Average
    • Facebook
    • X
    • LinkedIn
    • Pinterest
  • Focusing on Seven Services Could Eliminate More Than Two-Thirds of Low-Value Care in HCCI’s ESI Data

    Tags: ESI, LowValueCare, Spending, Utilization
    Focusing on Seven Services Could Eliminate More Than Two-Thirds of Low-Value Care in HCCI’s ESI Data
    Debra Bozzi, Aditi Sen, Katie Martin
    April 25, 2023

    There is substantial evidence that people in the U.S. receive health care services judged to be of low-value. These services are identified as low value based on recommendations from the U.S. Preventive Services Task Force (USPSTF) and professional medical societies that there is little to no clinical value associated with their provision and potential for…

    Read more: Focusing on Seven Services Could Eliminate More Than Two-Thirds of Low-Value Care in HCCI’s ESI Data
    • Facebook
    • X
    • LinkedIn
    • Pinterest
  • Insulin Prices in ESI Nearly Doubled from 2012-2021, with Effects of Emerging Biosimilars Evident in Recent Years

    Tags: Insulin, Prices
    Insulin Prices in ESI Nearly Doubled from 2012-2021, with Effects of Emerging Biosimilars Evident in Recent Years
    Bianca Silva Gordon, Aditi Sen, John Hargraves
    April 4, 2023

    Insulin is a life-saving medication for millions of Americans who live with diabetes. As the price of insulin has risen, people who depend on insulin have had to make difficult decisions about whether to pay for their medication or other necessities. Some have been forced to ration their supply, with devastating results. Recent legislation has limited insulin out-of-pocket costs at…

    Read more: Insulin Prices in ESI Nearly Doubled from 2012-2021, with Effects of Emerging Biosimilars Evident in Recent Years
    • Facebook
    • X
    • LinkedIn
    • Pinterest
  • Uptake of Biosimilars Remains Low Among People with Employer-Sponsored Insurance

    Tags: Biosimilars, Drug Spending
    Uptake of Biosimilars Remains Low Among People with Employer-Sponsored Insurance
    Jessica Chang, Aditi Sen
    March 30, 2023

    Biologic drugs represent advances in medical research and treatment but are a major driver of drug spending in the United States. Spending on biologics increased by 50% between 2014 and 2018 in the U.S. even though just 2% of Americans used them. Biosimilars, clinically equivalent, lower-cost versions of original biologic drugs, analogous to generic versions…

    Read more: Uptake of Biosimilars Remains Low Among People with Employer-Sponsored Insurance
    • Facebook
    • X
    • LinkedIn
    • Pinterest
  • Rising Share of Chemotherapy Services Provided in Outpatient Departments is Associated with Higher Costs for Patients and Payers

    Tags: Prices, SiteofService
    Rising Share of Chemotherapy Services Provided in Outpatient Departments is Associated with Higher Costs for Patients and Payers
    Jessica Chang, Aditi Sen
    March 28, 2023

    Every year, 1 million people in the U.S. receive chemotherapy for cancer treatment. Most chemotherapy treatment requires patients to be present in a physician’s office or hospital outpatient department to receive the treatment (typically an infusion or injection). Chemotherapy plays a critical role in treatment for many patients with cancer, but it also often leads…

    Read more: Rising Share of Chemotherapy Services Provided in Outpatient Departments is Associated with Higher Costs for Patients and Payers
    • Facebook
    • X
    • LinkedIn
    • Pinterest
  • HCCI Spotlights Colorectal Cancer Awareness Month: Use of Cologuard Doubled over 2018-2020, Despite Drops Early in the COVID-19 Pandemic

    HCCI Spotlights Colorectal Cancer Awareness Month: Use of Cologuard Doubled over 2018-2020, Despite Drops Early in the COVID-19 Pandemic
    Linsay Sarfo & Aditi Sen
    March 20, 2023

    Colorectal cancer screenings are essential for early disease detection, prevention, and treatment. Since 2014, Cologuard, a DNA-based screening test that can detect colorectal cancer and precancerous cells, has been available to individuals 45 and older at average risk for colorectal cancer. In contrast to colonoscopies, which must be done at a health care facility, Cologuard is…

    Read more: HCCI Spotlights Colorectal Cancer Awareness Month: Use of Cologuard Doubled over 2018-2020, Despite Drops Early in the COVID-19 Pandemic
    • Facebook
    • X
    • LinkedIn
    • Pinterest
  • HCCI Spotlights Colorectal Cancer Awareness Month: Colonoscopy Prep Drugs Underscore the Tradeoff Between Cost and Patient Preference

    HCCI Spotlights Colorectal Cancer Awareness Month: Colonoscopy Prep Drugs Underscore the Tradeoff Between Cost and Patient Preference
    Debra Bozzi, John Hargraves, Katie Martin, Aditi Sen
    March 17, 2023

    Colorectal cancer is the third most common cancer diagnosed in the U.S., and the second most common cause of cancer deaths among men and women combined. Screening via colonoscopy is highly effective in terms of improving prognosis of colorectal cancer via early detection; over 90% of patients who are diagnosed early (i.e., when the cancer is small…

    Read more: HCCI Spotlights Colorectal Cancer Awareness Month: Colonoscopy Prep Drugs Underscore the Tradeoff Between Cost and Patient Preference
    • Facebook
    • X
    • LinkedIn
    • Pinterest
«
1 … 4 5 6 7 8 … 21
»

Enhance your research using customized data analysis

Are you interested in a specific health care topic? HCCI can use our commercial and government data resources and unique analytic experience to help you. Just reach out!

Partner with us

About

We are a mission-driven, independent, nonprofit organization situated at the nexus of data, analytics, and action.

Contact

1100 G Street NW, Suite 600
Washington DC, 20005

info@healthcostinstitute.org
media@healthcostinstitute.org

Research

HCCI Publications
Research Resources

Data

Data Access Hub
Data Tools

Quick Links

Partner with HCCI
HCCI Newsletter
Careers

  • LinkedIn
  • X
  • Link
  • Bluesky

© 2025 Health Care Cost Institute Inc.
Unless explicitly noted, the content on this website is licensed under a Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

Scroll to Top